The new face of ovarian cancer modeling: Better prospects for detection and treatment

F1000 Medicine Reports

Volumn 3, Issue 1, 2011, Pages

  Karst, Alison M ^a,b,c   Drapkin, Ronny ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER DIAGNOSIS; CANCER MODEL; CARCINOGENESIS; EPITHELIUM CELL; EX VIVO STUDY; FEMALE; GENOMICS; HUMAN; HUMAN CELL; ONCOGENE; OVARY CANCER; TUMOR SUPPRESSOR GENE; UTERINE TUBE;

EID: 80655126745     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M3-22     Document Type: Article

References (29)

1. Kurman RJ, Shih Ie M: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010, 34:433-43. F1000 factor 10 Evaluated by Katharina Spanel-Borowski 22 Mar 2010
2. Karst AM, Drapkin R: Ovarian cancer pathogenesis: a model in evolution. J Oncol 2010, 2010:932371.
3. Levanon K, Crum C, Drapkin R: New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008, 26:5284-93.
4. Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y: The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol 2007, 19:3-9. (Pubitemid 46095865)
5. Dubeau L: The cell of origin of ovarian epithelial tumours. Lancet Oncol 2008, 9:1191-7.
6. Seidman JD, Zhao P, Yemelyanova A: "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol. 2011, 120:470-3.
7. Seidman JD, Yemelyanova A, Zaino RJ, Kurman RJ: The fallopian tube-peritoneal junction: a potential site of carcinogenesis. Int J Gynecol Pathol 2011, 30:4-11.
8. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-15. F1000 factor 10 Evaluated by Ronny Drapkin 20Oct 2011, Carlos Telleria 08Aug 2011
9. Pearce CL, Near AM, Van Den Berg DJ, Ramus SJ, Gentry-Maharaj A, Menon U, Gayther SA, Anderson AR, Edlund CK, Wu AH, Chen X, Beesley J, Webb PM, Holt SK, Chen C, Doherty JA, Rossing MA, Whittemore AS, McGuire V, DiCioccio RA, Goodman MT, Lurie G, Carney ME, Wilkens LR, Ness RB, Moysich KB, Edwards R, Jennison E, Kjaer SK, Hogdall E, et al.: Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer 2009, 100:412-20. F1000 factor 6 Evaluated by Ronny Drapkin 20 Oct 2011
10. Fasching PA, Gayther S, Pearce L, Schildkraut JM, Goode E, Thiel F, Chenevix-Trench G, Chang-Claude J, Wang-Gohrke S, Ramus S, Pharoah P, Berchuck A; OCAC (Ovarian Cancer Association Consortium): Role of genetic polymorphisms and ovarian cancer susceptibility. Mol Oncol 2009, 3:171-81. F1000 factor 6 Evaluated by Ronny Drapkin 20 Oct 2011
11. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemeney LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT, et al.: A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet 2010, 42:874-9. F1000 factor 6 Evaluated by Ronny Drapkin 20 Oct 2011
12. Etemadmoghadam D, deFazio A, Beroukhim R, Mermel C, George J, Getz G, Tothill R, Okamoto A, Raeder MB, Harnett P, Lade S, Akslen LA, Tinker AV, Locandro B, Alsop K, Chiew YE, Traficante N, Fereday S, Johnson D, Fox S, Sellers W, Urashima M, Salvesen HB, Meyerson M, Bowtell D; AOCS Study Group: Integrated genomewide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 2009, 15:1417-27. F1000 factor 6 Evaluated by Ronny Drapkin 20 Oct 2011
13. Notaridou M, Quaye L, Dafou D, Jones C, Song H, Høgdall E, Kjaer SK, Christensen L, Høgdall C, Blaakaer J, McGuire V, Wu AH, Van Den Berg DJ, Pike MC, Gentry-Maharaj A, Wozniak E, Sher T, Jacobs IJ, Tyrer J, Schildkraut JM, Moorman PG, Iversen ES, Jakubowska A, Medrek K, Lubiński J, Ness RB, Moysich KB, Lurie G, Wilkens LR, Carney ME, et al.: Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer 2011, 128:2063-74. F1000 factor 6 Evaluated by Ronny Drapkin 20 Oct 2011
14. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton- Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, et al.: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet 2010, 42:880-4. F1000 factor 6 Evaluated by Ronny Drapkin 20 Oct 2011
15. Vang R, Shih Ie M, Kurman RJ: Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009, 16:267-82.
16. Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N, Wang Y, Kurman RJ, Shih IeM, Wang TL: Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 2009, 69:4036-42.
17. Shih IeM, Chen L, Wang CC, Gu J, Davidson B, Cope L, Kurman RJ, Xuan J, Wang TL: Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am J Obstet Gynecol 2010, 203:584 e1-22.
18. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD: Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010, 221:49-56. F1000 factor 6 Evaluated by Ronny Drapkin 20 Oct 2011
19. Press JZ, De Luca A, Boyd N, Young S, Troussard A, Ridge Y, Kaurah P, Kalloger SE, Blood KA, Smith M, Spellman PT, Wang Y, Miller DM, Horsman D, Faham M, Gilks CB, Gray J, Huntsman DG: Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008, 8:17. F1000 factor 6 Evaluated by Ronny Drapkin 20 Oct 2011
20. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004, 4:814-9. F1000 factor 6 Evaluated by Ronny Drapkin 20 Oct 2011
21. Mukhopadhyay A, Curtin N, Plummer R, Edmondson RJ: PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine. BJOG 2011, 118:429-32. F1000 factor 6 Evaluated by Ronny Drapkin 20 Oct 2011
22. Levanon K, Ng V, Piao HY, Zhang Y, Chang MC, Roh MH, Kindelberger DW, Hirsch MS, Crum CP, Marto JA, Drapkin R: Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 2010, 29:1103-13.
23. Vermeer PD, Einwalter LA, Moninger TO, Rokhlina T, Kern JA, Zabner J, Welsh MJ: Segregation of receptor and ligand regulates activation of epithelial growth factor receptor. Nature 2003, 422:322-6. F1000 factor 19 Evaluated by Evaluated by Ronny Drapkin 20 Oct 2011, Steven Burden 14 Jul 2003, Sally Temple01 May 2003, Surender Kharbanda 25 Apr 2003, Charles Streuli 22 Apr 2003, Ben Zion Shilo 01 Apr 2003, Michel Labouesse 01 Apr 2003
24. Fotheringham S, Levanon K, Drapkin R: Ex Vivo Culture of Primary Human Fallopian Tube Epithelial Cells. J Vis Exp 2011, 9:pii 2728.
25. Maines-Bandiera SL, Kruk PA, Auersperg N: Simian virus 40- transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am J Obstet Gynecol 1992, 167:729-35. F1000 factor 6 Evaluated by Ronny Drapkin 20 Oct 2011
26. Tsao SW, Mok SC, Fey EG, Fletcher JA, Wan TS, Chew EC, Muto MG, Knapp RC, Berkowitz RS: Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res 1995, 218:499-507. F1000 factor 6 Evaluated by Ronny Drapkin 20 Oct 2011
27. Karst AM, Levanon K, Drapkin R: Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci U S A 2011, 108:7547-52.
28. Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, Scott JA, East A, Ali LD, Lizotte PH, Wong TC, Jiang G, Hsiao J, Mermel CH, Getz G, Barretina J, Gopal S, Tamayo P, Gould J, Tsherniak A, Stransky N, Luo B, Ren Y, Drapkin R, Bhatia SN, Mesirov JP, Garraway LA, Meyerson M, Lander ES, Root DE, Hahn WC: Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A 2011, 108:12372-7.
29. Greene MH, Mai PL, Schwartz PE: Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol 2011, 204:19 e1-6. F1000 factor 6 Evaluated by Ronny Drapkin 20 Oct 2011